Home Multimedia Podcasts IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES June 19, 2008 – Interview with Sharon Terry, President and CEO of the Genetic Alliance /wp-content/uploads/2018/09/gc215_6_19_2008.mp3 Clinical laboratory techniqueDiagnosisDiagnostic techniquesGenetic testing (Diagnostic technique)Medicine, Diagnosis, and TherapeuticsMolecular technique Also of Interest StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies AI Detects Cancer via DNA Repeats in Liquid Biopsies Epstein-Barr Virus Has Vulnerable Sites Exposed 89bio’s MASH Drug Begins Phase III, Aiming to Stand Out in Growing Field StockWatch: Madrigal Shares Soar as FDA Nears Historic MASH Decision Related Media Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Emerging Markets Collaborate to Succeed in Post-Pandemic World Breathing Oxygen Back into the Biological Conversation Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Related Content StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies AI Detects Cancer via DNA Repeats in Liquid Biopsies Epstein-Barr Virus Has Vulnerable Sites Exposed